{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"17"}],"title":"Number of participants who experienced an AE meeting the Dose-Limiting Toxicity definition"},{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"64"}],"title":"Number of participants who did not experience an AE meeting the Dose-Limiting Toxicity definition"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"81"}],"units":"Participants"}],"description":"The safety of the T cell infusion at the maximum tolerated dose determined in Phase 1, and further characterized in Phase 2, will be described","groups":[{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^5 CAR T cells/kg","id":"OG000","title":"Phase 1 - Cohort 1A"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^6 CAR T cells/kg","id":"OG001","title":"Phase 1-Cohort 1B"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^6 CAR T cells/kg","id":"OG002","title":"Phase 1-Cohort 1C"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^7 CAR T cells/kg","id":"OG003","title":"Phase 1-Cohort 1D"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide","id":"OG004","title":"Phase 1-Cohort 1F1"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide","id":"OG005","title":"Phase 1-Cohort 1F2"},{"description":"The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\\^6 CAR T cells/kg following lymphodepletion if indicated","id":"OG006","title":"Phase 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Phase 1 cohorts: Toxicity-evaluable leukemia patients who received CAR T cells; Phase 2 cohort: Toxicity-evaluable leukemia patients treated with the Phase 2 dose, 1 x 10\\^6 CAR T cells/kg, following lymphodepletion with fludarabine and cyclophosphamide","reportingStatus":"POSTED","timeFrame":"Initial CAR T cell infusion through 30 days post infusion","title":"Number of Participants Who Experienced an Adverse Event Meeting the Dose-Limiting Toxicity Definition","type":"PRIMARY","unitOfMeasure":"Participants"}